IBOHealthcare · BiotechnologyIBO Stock Forecast: Impact BioMedical, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
IBO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Impact BioMedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Impact BioMedical, Inc. — and when they’d sell — is the membership.
IBO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IBO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IBO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Impact BioMedical, Inc. (IBO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.7×
- Price / sales
- 1188.8×
- Price / book
- 4.1×
- EV / EBITDA
- −12.3×
Cheaper than 65% of US stocks
Cheaper than 1% of US stocks
Cheaper than 26% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- 0.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −32700.0%
- Net margin
- −1225.0%
Higher than 29% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
- Return on equity
- −119.7%
- Return on assets
- −18.7%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IBO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBO appears on the weeks it earns a place.
Frequently asked questions about IBO stock
How does Ticker Nerd's model rank IBO?
As at 1 Aug 2026, Impact BioMedical, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
What is the IBO stock forecast for 2030?
No analyst covering Impact BioMedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBO are extrapolating price history, which says nothing about the business.
How has IBO stock performed over the past year?
Impact BioMedical, Inc. returned -28.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Impact BioMedical, Inc. do?
Impact Biomedical Inc. is a pioneering company within the biotechnology sector, focused on developing innovative solutions that address key challenges in health and wellness.
About Impact BioMedical, Inc.
Impact Biomedical Inc. is a pioneering company within the biotechnology sector, focused on developing innovative solutions that address key challenges in health and wellness. The primary function of Impact Biomedical Inc. is to research and create cutting-edge biotechnologies that have the potential to significantly impact pharmaceuticals, cosmetics, and other health-related industries. Notable features of the company include its strong emphasis on developing anti-pathogenic compounds, next-generation health supplements, and immunotherapy treatments. Impact Biomedical collaborates with research institutions and global partners to leverage scientific advancements and bring novel products to the market. As a player in the biotech market, Impact Biomedical Inc. plays a crucial role in advancing medical science and providing tools that combat health threats, contributing to the overall development and enhancement of public health solutions. Its innovations are particularly significant as they promise improvements in treatment efficacy and accessibility, thereby influencing various sectors aligned with health and disease prevention.
CEO Mr. Frank D. Heuszel Esq., J.D. · 2 employees · United States · https://www.impactbiomedinc.com